These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 19168795)

  • 1. PKCbeta is essential for the development of chronic lymphocytic leukemia in the TCL1 transgenic mouse model: validation of PKCbeta as a therapeutic target in chronic lymphocytic leukemia.
    Holler C; Piñón JD; Denk U; Heyder C; Hofbauer S; Greil R; Egle A
    Blood; 2009 Mar; 113(12):2791-4. PubMed ID: 19168795
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CD5+CD23+ leukemic cell populations in TCL1 transgenic mice show significantly increased proliferation and Akt phosphorylation.
    Efanov A; Zanesi N; Nazaryan N; Santanam U; Palamarchuk A; Croce CM; Pekarsky Y
    Leukemia; 2010 May; 24(5):970-5. PubMed ID: 20357824
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of rapamycin on mouse chronic lymphocytic leukemia and the development of nonhematopoietic malignancies in Emu-TCL1 transgenic mice.
    Zanesi N; Aqeilan R; Drusco A; Kaou M; Sevignani C; Costinean S; Bortesi L; La Rocca G; Koldovsky P; Volinia S; Mancini R; Calin G; Scott CP; Pekarsky Y; Croce CM
    Cancer Res; 2006 Jan; 66(2):915-20. PubMed ID: 16424025
    [TBL] [Abstract][Full Text] [Related]  

  • 4. ROR1 can interact with TCL1 and enhance leukemogenesis in Eμ-TCL1 transgenic mice.
    Widhopf GF; Cui B; Ghia EM; Chen L; Messer K; Shen Z; Briggs SP; Croce CM; Kipps TJ
    Proc Natl Acad Sci U S A; 2014 Jan; 111(2):793-8. PubMed ID: 24379361
    [TBL] [Abstract][Full Text] [Related]  

  • 5. miR-181b as a therapeutic agent for chronic lymphocytic leukemia in the Eµ-TCL1 mouse model.
    Bresin A; Callegari E; D'Abundo L; Cattani C; Bassi C; Zagatti B; Narducci MG; Caprini E; Pekarsky Y; Croce CM; Sabbioni S; Russo G; Negrini M
    Oncotarget; 2015 Aug; 6(23):19807-18. PubMed ID: 26090867
    [TBL] [Abstract][Full Text] [Related]  

  • 6. PTPROt-mediated regulation of p53/Foxm1 suppresses leukemic phenotype in a CLL mouse model.
    Motiwala T; Kutay H; Zanesi N; Frissora FW; Mo X; Muthusamy N; Jacob ST
    Leukemia; 2015 Jun; 29(6):1350-9. PubMed ID: 25482129
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Human chronic lymphocytic leukemia modeled in mouse by targeted TCL1 expression.
    Bichi R; Shinton SA; Martin ES; Koval A; Calin GA; Cesari R; Russo G; Hardy RR; Croce CM
    Proc Natl Acad Sci U S A; 2002 May; 99(10):6955-60. PubMed ID: 12011454
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lessons learned from the Eµ-TCL1 mouse model of CLL.
    Floerchinger A; Seiffert M
    Semin Hematol; 2024 Jun; 61(3):194-200. PubMed ID: 38839457
    [TBL] [Abstract][Full Text] [Related]  

  • 9. B cell receptors in TCL1 transgenic mice resemble those of aggressive, treatment-resistant human chronic lymphocytic leukemia.
    Yan XJ; Albesiano E; Zanesi N; Yancopoulos S; Sawyer A; Romano E; Petlickovski A; Efremov DG; Croce CM; Chiorazzi N
    Proc Natl Acad Sci U S A; 2006 Aug; 103(31):11713-8. PubMed ID: 16864779
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Accelerated progression of chronic lymphocytic leukemia in Eμ-TCL1 mice expressing catalytically inactive RAG1.
    Nganga VK; Palmer VL; Naushad H; Kassmeier MD; Anderson DK; Perry GA; Schabla NM; Swanson PC
    Blood; 2013 May; 121(19):3855-66, S1-16. PubMed ID: 23502221
    [TBL] [Abstract][Full Text] [Related]  

  • 11. TCL1 transgenic mouse model as a tool for the study of therapeutic targets and microenvironment in human B-cell chronic lymphocytic leukemia.
    Bresin A; D'Abundo L; Narducci MG; Fiorenza MT; Croce CM; Negrini M; Russo G
    Cell Death Dis; 2016 Jan; 7(1):e2071. PubMed ID: 26821067
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Syk inhibitor fostamatinib disodium (R788) inhibits tumor growth in the Eμ- TCL1 transgenic mouse model of CLL by blocking antigen-dependent B-cell receptor signaling.
    Suljagic M; Longo PG; Bennardo S; Perlas E; Leone G; Laurenti L; Efremov DG
    Blood; 2010 Dec; 116(23):4894-905. PubMed ID: 20716772
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Characterization of the TCL-1 transgenic mouse as a preclinical drug development tool for human chronic lymphocytic leukemia.
    Johnson AJ; Lucas DM; Muthusamy N; Smith LL; Edwards RB; De Lay MD; Croce CM; Grever MR; Byrd JC
    Blood; 2006 Aug; 108(4):1334-8. PubMed ID: 16670263
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CD74 is dispensable for development of chronic lymphocytic leukemia in
    Barthel R; Fedorchenko O; Velmans T; Rosen N; Nguyen PH; Reinart N; Florin A; Herling M; Hallek M; Fingerle-Rowson G
    Leuk Lymphoma; 2020 Dec; 61(12):2799-2810. PubMed ID: 32667245
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Overexpression of TCL1 activates the endoplasmic reticulum stress response: a novel mechanism of leukemic progression in mice.
    Kriss CL; Pinilla-Ibarz JA; Mailloux AW; Powers JJ; Tang CH; Kang CW; Zanesi N; Epling-Burnette PK; Sotomayor EM; Croce CM; Del Valle JR; Hu CC
    Blood; 2012 Aug; 120(5):1027-38. PubMed ID: 22692508
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Regulation of Akt/PKB by phosphatidylinositol 3-kinase-dependent and -independent pathways in B-cell chronic lymphocytic leukemia cells: role of protein kinase C{beta}.
    Barragán M; de Frias M; Iglesias-Serret D; Campàs C; Castaño E; Santidrián AF; Coll-Mulet L; Cosialls AM; Domingo A; Pons G; Gil J
    J Leukoc Biol; 2006 Dec; 80(6):1473-9. PubMed ID: 16940331
    [TBL] [Abstract][Full Text] [Related]  

  • 17. High TCL1 levels are a marker of B-cell receptor pathway responsiveness and adverse outcome in chronic lymphocytic leukemia.
    Herling M; Patel KA; Weit N; Lilienthal N; Hallek M; Keating MJ; Jones D
    Blood; 2009 Nov; 114(21):4675-86. PubMed ID: 19770358
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Par-4 overexpression impedes leukemogenesis in the Eµ-TCL1 leukemia model through downregulation of NF-κB signaling.
    Greene JT; Mani R; Ramaswamy R; Frissora F; Yano M; Zapolnik K; Harrington B; Wasmuth R; Tran M; Mo X; McKenna M; Rangnekar VM; Byrd JC; Bondada S; Muthusamy N
    Blood Adv; 2019 Apr; 3(8):1255-1266. PubMed ID: 30987970
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tcl1 protein functions as an inhibitor of de novo DNA methylation in B-cell chronic lymphocytic leukemia (CLL).
    Palamarchuk A; Yan PS; Zanesi N; Wang L; Rodrigues B; Murphy M; Balatti V; Bottoni A; Nazaryan N; Alder H; Rassenti L; Kipps TJ; Freitas M; Croce CM; Pekarsky Y
    Proc Natl Acad Sci U S A; 2012 Feb; 109(7):2555-60. PubMed ID: 22308499
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Chronic lymphocytic leukemia and regulatory B cells share IL-10 competence and immunosuppressive function.
    DiLillo DJ; Weinberg JB; Yoshizaki A; Horikawa M; Bryant JM; Iwata Y; Matsushita T; Matta KM; Chen Y; Venturi GM; Russo G; Gockerman JP; Moore JO; Diehl LF; Volkheimer AD; Friedman DR; Lanasa MC; Hall RP; Tedder TF
    Leukemia; 2013 Jan; 27(1):170-82. PubMed ID: 22713648
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.